Form 4: Illumina Executive Kathryne Gambrell Reeves Reports Stock and Performance Share Transactions

Kathryne Gambrell Reeves, SVP and Chief Marketing Officer of Illumina, reports the acquisition of restricted stock units and performance shares, along with the disposal of some common stock.

Summary

• On March 5, 2024, Kathryne Gambrell Reeves, SVP and Chief Marketing Officer of Illumina, reported transactions involving Illumina's stock.
• Reeves acquired 5,569 shares of common stock at $0 price.
• Reeves disposed of 17,965 shares of common stock.
• Reeves was granted 6,497 performance shares tied to the company's three-year average operating margin for fiscal years 2024-2026, vesting on January 3, 2027.
• The number of shares issued for the operating margin performance shares will range from 0% to 200% of the specified amount, based on the company's actual performance relative to pre-defined objectives.
• Reeves also acquired 6,497 performance shares tied to the company's relative total shareholder return for the fiscal year ending January 3, 2027.
• The number of shares issued for the shareholder return performance shares will range from 0% to 200% of the specified amount, based on the company's performance relative to pre-defined objectives.
• The reporting person directly owns 6,497 performance shares.
• The reporting person directly owns 6,497 performance shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The acquisition of shares and performance shares is positive, but the disposal of shares is a slight negative. The overall impact is likely minimal.

Positives

• The grant of performance shares to a key executive aligns their interests with the company's long-term performance.

Negatives

• The disposal of 17,965 shares by a top executive could be interpreted negatively by the market, although the reason for the disposal is not specified.

Risks

• The value of the performance shares is contingent on Illumina achieving specific operating margin and shareholder return targets, which are subject to market conditions and company performance.
• The executive must remain a service provider until the vesting date to receive the performance shares.

Future Outlook

The performance shares are contingent on Illumina's future performance regarding operating margin and shareholder return over the next few years.

Industry Context

Executive stock transactions are common in publicly traded companies and are regularly monitored by investors for insights into management's confidence in the company's prospects. Performance-based compensation is a standard practice to align executive incentives with shareholder value.

Comparison to Industry Standards

• Stock grants and performance-based equity are common compensation tools in the biotechnology industry, used by companies like Thermo Fisher Scientific, Danaher, and Agilent to incentivize executives.
• The vesting schedules and performance metrics (operating margin, TSR) are typical for executive compensation packages in this sector.
• The range of 0-200% payout for performance shares is also within the typical range seen in similar companies.

Stakeholder Impact

• The stock transactions may have a minor impact on shareholders' perception of the company.
• The performance-based compensation structure incentivizes the executive to drive company performance, which benefits shareholders and employees.

Key Dates